Earlier, the company has received orphan drug status for CYT387 for the treatment of myelofibrosis from the US Food and Drug Administration (FDA).
YM BioSciences president and CEO Nick Glover said CYT387 has demonstrated early efficacy in improving the key aspects of myelofibrosis including anemia, splenomegaly and a range of debilitating symptoms.
"Having our JAK inhibitor designated as an orphan drug for the treatment of myelofibrosis in Europe, in addition to our previously obtained orphan designation in the US, will help ensure that we are able to advance this drug as efficiently as possible for these patient groups," Glover said.